ROBOSENSE
9.2.2021 20:02:05 CET | Business Wire | Press release
RoboSense LiDAR (https://robosense.ai/ ) today released the latest version of the ground truth data system and evaluation tool chain RS-Reference 2.1, used for LiDARs and multi-sensor fusion systems performance evaluation. The original RS-Reference version was launched in the market in 2016, when the automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 project was established. Used by global OEMs and Tier1s, the system has been continuously improved and upgraded with more efficient and useful evaluation function modules and software tool chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005689/en/
While the evaluation function modules can be liked to an exam, the ground truth data is the "answer" for the evaluation of the perception system. Therefore, the accuracy of ground truth data must be significantly higher than the device under test (DuT) in all aspects including detection performance and geometric error.
The ground truth data, usually stored in the PB-Level, includes dynamic information such as obstacle types, speeds, and locations, and static information such as lane lines and road boundaries.
Data labeling quality and data generation efficiency are the key factors to ground truth data.
- The RS-Reference system provides a set of ground truth data generation and evaluation solutions, and outputs detection performance and geometric error indicators with a labeling efficiency close to 1:1. This is significantly more accurate than real-time perception, manual labeling and traditional labeling tools.
- High performance and mature sensor data collection system: the RS-Reference system contains the RoboSense 128-beam LiDAR RS-Ruby, Leopard camera, Continental 408 millimeter-wave radar, GI-6695 RTK, and two added RoboSense RS-Bpearl LiDAR for near-field blind spots in the 2.1 version.
- Detached roof-mounted deployment without vehicle body modification: the RS-Reference system adapts to different vehicle sizes, does not occupy the sensor installation position of the DuTs, and directly evaluates the intelligent driving system that is consistent with the sensor sets of commercial vehicles.
- Vastly improved/accumulated perception algorithm and offline processing mechanism: The algorithm is key to smart labeling instead of manual labeling, and is responsible for the extraction of ground truth data. The RS-Reference system uses a customized and dedicated offline perception algorithm, which is the product of RoboSense’s 13+ years’ of accumulated experience of LiDAR sensing algorithm technology. It performs a “full life process tracking and identification" for each obstacle data, and extracts all ground truth data from each frame. The RS-Reference system can pick up speed and acceleration labeling, and accurately delineate the size of the labeling frame through comprehensive shape and size information. The system is also capable of accurately dividing obstacles that are in close proximity to each other in complex scenes.
- Full-stack evaluation tool chain: it includes data collection tools, sensor calibration tools, visualization tools, manual verification tools, evaluation tools, etc. The 2.1 version upgrades the data management platform and adds the scene semantic labeling function that serves every step of the evaluation process.
- Individual sensor evaluation in the multi-sensor fusion system: not only can the RS-Reference system evaluate the result of intelligent driving's perception fusion, but it can also provide targeted solutions based on the features of different types of sensors such as LiDAR, millimeter wave radar, and camera. Dedicated or customized tool modules can be developed according to customer needs for further in-depth analysis of the performance of the sensing system.
- Extended application value of the RS-Reference: includes planning and control algorithm development support, which is able to generate massive ground truth data to build simulation scenes, and can evaluate road-side perception systems.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005689/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom